Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib

Acquired resistance of metastatic melanoma (MM) tumors to BRAF V600E inhibitors (BRAFi’s) is commonplace in the clinic. Habitual relapse of patients contributes to <20% 5-year survival rates in MM. We previously identified serine synthesis as a critical detrminant of late-stage cancer cell resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Kayleigh C., Chin, Kevin F., Kim, Daehwan, Marion, Christopher D., Yen, Timothy J., Bhattacharjee, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862581/
https://www.ncbi.nlm.nih.gov/pubmed/29568360
http://dx.doi.org/10.18632/oncotarget.24341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862581/
https://www.ncbi.nlm.nih.gov/pubmed/29568360
http://dx.doi.org/10.18632/oncotarget.24341

Ejemplares similares